Compare Neurocrine Biosciences Inc (NBIX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs VF Corp — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while VF Corp trades at $14.92 (market cap $5.71B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.6× VF Corp's market cap, and VF Corp pays a 2.48% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and VF Corp for 64 Days on average.
| NBIX | VFC | |
|---|---|---|
Market Cap | $14.60B | $5.71B |
Volume | 1,075,694 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $21.55 |
52-Week Low | $123.10 | $12.62 |
Typical Hold Time | 23 Days | 64 Days |
Enterprise Value | $14.61B | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
VFC trades at $14.38, down 0.48% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock is near its 52-week low, reflecting ongoing challenges. Recent earnings have been volatile, with two misses in the last three quarters, and the company reported a net loss of $189.72 million for 2025. Revenue has declined from $11.8 billion in 2022 to $9.5 billion in 2025, though 2026 projects a return to profitability.
The outlook for VFC hinges on executing its turnaround amid weak Vans performance. The stock's discounted valuation (P/E of 20.84, P/S of 0.6) offers potential upside if brand recovery gains traction, but high execution risk and competitive pressures pose significant threats. Analyst consensus is mixed with a Hold rating, and the stock faces near-term resistance at $15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
